Source disclosure: February 26, 2026, 15:30 JST
D.Western Therapeutics Institute, Inc. [4576.T]
TOKYO, Feb 26 (Pulse News Wire) – D.Western Therapeutics Institute, Inc. (4576.T) reported its fiscal fourth quarter earnings on February 13, 2026.
During a subsequent analyst meeting held on February 20, 2026, management addressed key pipeline developments and future plans. Regarding the China-based DW-2206 project, clinical trials initially planned for 2025 did not commence due to licensing changes. However, discussions with authorities suggest potential initiation in 2026. Similarly, DW-1002 missed its 2025 launch target but is expected to go public in 2026, though royalty income will not accrue due to expired patents. In Japan, the company is working towards regulatory approval using U.S.
Data, aiming for an early application despite ongoing negotiations with PMDA. Management also outlined strategies to increase market capitalization beyond ¥1 trillion, targeting a breakthrough past ¥1.5 trillion through successful late-stage product launches. They emphasized reducing valuation discounts and achieving revenue growth as priorities. On the H-1337 project, discussions with the FDA focused on optimizing Phase 3 trial protocols to reduce costs while ensuring safety standards. Financially, the company expects sufficient cash reserves to last two to two-and-a-half years, contingent upon funding needs for major trials.
AI-translated content. 🟢 Confidence: High See terms • Original filing